A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
about
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanismToxic myopathiesMuscular effects of statins in the elderly female: a reviewVigorous exercise and diabetic, hypertensive, and hypercholesterolemia medication use.Mechanisms and assessment of statin-related muscular adverse effects.Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathwaysStatin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum".Statin use and musculoskeletal pain among adults with and without arthritis.Lessons from france: the cardiovascular prevention clinic in the la pitié-salpêtrière hospital in paris.Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveAutoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyRarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.Fibrates in combination with statins in the management of dyslipidemia.The Effect of Atorvastatin on Habitual Physical Activity among Healthy Adults.SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese RatsPrevalence of musculoskeletal pain and statin use.High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.Statin myopathy as a metabolic muscle disease.Molecular basis for statin-induced muscle toxicity: implications and possibilities.Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia.The effects of statin medications on aerobic exercise capacity and training adaptations.Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of StatinsPrevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.PPARdelta agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction.Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.Statin use and pain in older people with cancer: a cross-sectional study.Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury.An insight into statin use and its association with muscular side effects in clinical practice.Statins everyday versus alternate days: Is there a difference in myalgia rates?
P2860
Q24603957-8D480B7C-8450-41A4-859E-B644D71E28ACQ27007256-59B524DF-77CD-4801-A7BD-684C7BBA7AF5Q27023343-19623666-8405-4883-9A5F-3D21DB69D0D3Q33639162-6E65CE20-429A-457E-8904-3B0C0B501C0BQ34570995-CAC11C51-9EA1-4B63-B2F0-E26C1B5C5078Q34578989-5CB20175-33A4-499A-B66A-43E257E61644Q34654243-F5FE2029-6EB6-4B63-AF96-C40E7AC11A1BQ35697228-77B4D9A2-F034-4F17-91B6-DE6F9BBFA01FQ35741915-6748BEF2-EA52-4177-9D2F-0C9D8BB709EAQ35793619-E1257C2C-52FA-49CB-8F43-4209625C63B8Q35909737-8AF95A81-D6CC-4DCB-ACA9-0C332008A073Q36154282-C175B205-132E-4FC2-9D2F-CDDEF8603451Q36366283-502DFC65-3DC7-46F4-9BFA-087FFE83566FQ36378125-F6B757B4-EA20-4C5B-9591-59014CC25CEAQ36480609-4F076632-5F9B-4F7C-B288-3D85FE398491Q36640423-FB0E37FC-4FE1-4F40-92DB-B0474E9C38EAQ36841011-EB4E433B-7DAB-4243-86DA-09A02C5A5E5AQ36979363-3DAB1C6E-48A8-4DFB-B75C-6A7D376D746BQ37230388-67242AED-F867-48B3-909F-0269DDF9BCD8Q37235648-3A29A455-19C3-4244-B099-970403EEF109Q37826757-C5B1FA0B-B4A7-4EE0-9D71-3C841CD672E8Q37886653-B61CC72D-03FC-4B7C-8A64-F45B686101BAQ38092053-D23C74AE-3FE8-4188-92F2-E5E9A21FE69DQ38219487-AC4BF010-6A95-4A8D-8B50-73077FCF6D56Q38228143-25301069-0DD8-41C5-97DE-3DB68DE92953Q38272551-A0D72CF3-2EB4-456A-B2C9-BF7BE6E655DAQ38924930-A4F3AACA-C13B-471D-9503-9C02E2CBC0F5Q41690509-7414C269-DE95-4396-A077-34471C9A418FQ46053075-1FFA2553-7BA2-4A16-BC0B-9E1775C896B8Q46686112-44DB18CF-7722-4892-A616-6AA1E4EB9C09Q46975648-B9D20967-1006-4E33-BB45-6227AC38F843Q49627163-C6B548AB-E2A6-4945-B428-01E63114A810Q54244380-C6E33125-8181-4374-A364-00FBAF00338DQ56975988-1AE726C2-6C94-4B1F-B29B-B93E8E1E363E
P2860
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@en
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@nl
type
label
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@en
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@nl
prefLabel
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@en
A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
@nl
P2093
P1476
A comprehensive description of muscle symptoms associated with lipid-lowering drugs
@en
P2093
Eric Bruckert
Gérard Turpin
Marina Chauvenet
Philippe Giral
Sylvie Dejager
P304
P356
10.1023/B:CARD.0000015861.26111.AB
P50
P577
2003-09-01T00:00:00Z